October 9, 2024 12:31 PM EDTUpdated 12:55 PM
FDA+

Cov­er­ing obe­si­ty drugs could cost Medicare $35B by 2034, CBO says

Max Bayer

Pharma Reporter

While Medicare doesn’t cur­rent­ly cov­er an­ti-obe­si­ty drugs, a new re­port from the Con­gres­sion­al Bud­get Of­fice es­ti­mates that cov­er­age could cost Medicare $35 bil­lion from 2026 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times